U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07183319) titled 'Circulating Tumor DNA Response In Urothelial Cancer' on Sept. 02.
Brief Summary: The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab & Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Intervention:
DRUG: Standard Dose (PEV)
Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.
DRUG: De-escalation Phase
Patients will receive 400 mg o...